Bruton protein-tyrosine kinase (BTK) FDA-approved small molecule inhibitors used for the management of neoplastic and inflammatory disorders
Six FDA-approved BTK inhibitors now treat both blood cancers and autoimmune diseases, giving doctors expanding options for patients who previously had limited therapies.
This review systematically covers all six FDA-approved BTK inhibitors, detailing their mechanisms, clinical indications in B-cell malignancies and autoimmune diseases, and the landmark 2025 expansion into non-oncologic use. It provides a comprehensive reference for clinicians navigating the rapidly evolving BTK inhibitor landscape across hematologic cancers and immune disorders.
What the study was
- Study design
- Comprehensive drug review
- Population
- Patients with B-cell malignancies (CLL, MCL, FL, MZL, WM) and chronic immune diseases
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Pharmacological Research
Why it surfaced
Comprehensive review of all FDA-approved BTK inhibitors including landmark 2025 non-oncologic approvals. High clinical utility for hematology/oncology and immunology practitioners. Directly addresses CLL, MCL, FL, MZL, and WM from the watchlist.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.